7月23日夜盘，法国生物技术公司Abivax（ABVX）股价大涨5.67%，引发市场广泛关注。这一显著涨幅源于该公司公布了其核心药物obefazimod在治疗溃疡性结肠炎方面取得的突破性临床试验结果。
根据Abivax发布的公告，obefazimod在针对中度至重度活动性溃疡性结肠炎的ABTECT III期临床试验中取得了积极成果。试验结果显示，在8周诱导期内，obefazimod在实现临床缓解方面明显优于安慰剂。其中，50mg剂量组实现了16.4%的安慰剂校正临床缓解率，具有高度统计学显著性和临床意义。
这一突破性进展不仅为溃疡性结肠炎患者带来新的治疗希望，也大大提升了投资者对Abivax前景的信心。公司表示计划在2026年下半年向美国食品药品监督管理局（FDA）提交新药申请。值得注意的是，obefazimod作为一种口服小分子药物，其独特的作用机制使其有潜力用于治疗多种炎症性疾病，这进一步扩大了该药物的市场前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.